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A survey on the epidemiological situation, surveil-
lance and containment activities for carbapenemase-
producing Enterobacteriaceae (CPE) was conducted 
in European countries in 2018. All 37 participating 
countries reported CPE cases. Since 2015, the epide-
miological stage of CPE expansion has increased in 11 
countries. Reference laboratory capability, dedicated 
surveillance and a specific national containment plan 
are in existence in 33, 27 and 14 countries, respec-
tively. Enhanced control efforts are needed for CPE 
containment in Europe.
The rapid worldwide dissemination of carbapene-
mase-producing Enterobacteriaceae (CPE) repre-
sents a global threat to patient safety and healthcare 
systems [1,2]. While data based on invasive iso-
lates from the European Antimicrobial Resistance 
Surveillance Network (EARS-Net) show stable propor-
tions of carbapenem resistance in  Klebsiella pneu-
moniae and Escherichia coli  for the last 4 years in the 
European Union (EU)/European Economic Area (EEA) 
as a whole, there is considerable heterogeneity across 
EU/EEA countries, with proportions of carbapenem 
resistance in  K. pneumoniae  invasive isolates ranging 
from 0 to 65% in 2017 [3]. Furthermore, there are recent 
reports of spread of CPE in individual European coun-
tries [4-7].
In 2017, the European Centre for Disease Prevention and 
Control (ECDC) established the European Antimicrobial 
Resistance Genes Surveillance Network (EURGen-Net) 
to perform structured surveys of carbapenem- and/or 
colistin-resistant Enterobacteriaceae (CCRE) in Europe, 
building on the ’European Survey of Carbapenemase-
Producing Enterobacteriaceae (EuSCAPE)’ project 
[8-10]. This network continues to support laboratory 
capacity building for detection and surveillance of 
CCRE in Europe. To determine the current epidemio-
logical situation of CPE and the national capacity for 
surveillance and containment of CPE and/or carbape-
nem-resistant Enterobacteriaceae (CRE), a question-
naire was sent to national experts from 30 EU/EEA and 
seven EU candidate or potential candidate countries 
in June 2018. Here, we present the results of the 2018 
assessment and compare them with previous assess-
ments using the same methodology.
EURGen-Net capacity survey and 
epidemiological staging system
The epidemiological staging system for measuring 
the extent of CPE spread across healthcare facilities 
was developed in 2010 and used in similar surveys in 
2010, 2013 and 2015 [8,9,11]. The system consists of 
seven consecutive stages (0, 1, 2a, 2b, 3, 4 and 5) that 
describe national spread of CPE, from no cases (stage 0) 
to an endemic situation (stage 5) as reported in Figure 
1. For EURGen-Net, the decision was made to extend 
the scope from CPE to CRE. Therefore, in this follow-
up survey for the assessment of country capacity, both 
definitions were used as indicated in this manuscript. 
National experts representing all 37 invited European 
countries completed this 2018 capacity survey. Their 
answers were based on knowledge of national surveil-
lance data and/or their professional experience at the 
National Reference/Expert laboratory, Public Health 
institute or Ministry of Health. For the UK, individual 
replies regarding capacity for surveillance and con-
tainment were provided for England, Northern Ireland, 
Wales and Scotland, and the corresponding informa-
tion is reported separately where relevant.
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Figure 1
Comparison of epidemiological stages of carbapenemase-producing Enterobacteriaceae in European countries, 2010–2018 
(n = 37)
Country 
Epidemiological stage for the spread of 
carbapenemase-producing Enterobacteriaceae 
Change in 
epidemiological 
stage 2015–18 2010 [11]  2013 [9] 2014–15 [8]  2018 
Albania NA 2a 1 1 → 
Austria 0 2b 2b 2b → 
Belgium 2b 3 4 4 → 
Bosnia and Herzegovinaa 1 1 0 2b ↑  
Bulgaria 0 2a 2a 2b → 
Croatia 1 3 3 4 ↑  
Cyprus 2a 2a 1 2a ↑  
Czech Republic 1 2b 2b 3 ↑  
Denmark 1 2a 4 4 → 
Estonia 0 2a 1 1 → 
Finland 1 2a 2a 3 ↑  
France 3 3 4 4 → 
Germany 3 3 3 3 → 
Greece 5 5 5 5 → 
Hungary 3 4 4 4 → 
Iceland 0 0 0 1 ↑  
Ireland 1 4 3 4 ↑  
Italy 4 5 5 5 → 
Kosovob NA 2b 0 1 ↑  
Latvia 1 1 1 1 → 
Lithuania 1 1 1 1 → 
Luxembourg NA 1 1 1 → 
Malta 1 5 5 5 → 
Montenegro NA 0 1 1 → 
The Netherlands 2a 2b 2a 2b → 
Norway 2a 2a 1 1 → 
Poland 4 3 4 4 → 
Portugal 1 1 2b 3 ↑  
Romania 1 1 4 4 → 
Serbia 1 1 2b 4 ↑  
Slovak Republic NA 2a 4 4 → 
Slovenia 0 1 2a 1 ↓  
Spain 2b 3 4 4 → 
Sweden 2a 2b 2a 2b → 
North Macedonia NA 0 1 2a ↑  
Turkey NA 2a 5 5 → 
United Kingdomc 2b 3 3 3 → 
↑: increase in the epidemiological stage between 2015 and 2018
 
→: unchanged epidemiological stage between 2015 and 2018 
↓: decreased epidemiological stage between 2015 and 2018
 
Epidemiological stages 
Stage 0: no case reported
 Stage 1: sporadic occurrence (epidemiologically unrelated single cases)
 
Stage 2a: single hospital outbreak (two or more epidemiologically associated cases with 
indistinguishable geno- or phenotype in a single institution)
Stage 2b: sporadic hospital outbreaks (unrelated hospital outbreaks with epidemiologically 
unrelated introduction or different strains, no autochthonous inter-institutional transmission reported)
Stage 3: regional spread (more than one epidemiologically related hospital outbreak confined to hospitals 
that are part of the same region or health district, indicating regional autochthonous inter-institutional transmission)
Stage 4: inter-regional spread (multiple epidemiologically related outbreaks occurring in different health districts, 
indicating inter-regional autochthonous inter-institutional transmission)
Stage 5: endemic situation (most hospitals in a country are repeatedly seeing cases admitted from autochthonous sources)
NA: no data available.
a The results reported for Bosnia and Herzegovina only apply to Republika Srpska.
b This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the 
International Court of Justice Opinion on the Kosovo declaration of independence.
c The results reported are for the United Kingdom (UK) overall. The epidemiological stages vary between regions within the UK.
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Epidemiological situation of 
carbapenemase-producing 
Enterobacteriaceae
In 2018, all 37 participating countries reported CPE 
cases, whereas in 2015, three countries had still not 
identified a single case [8]. Overall, 11 countries 
reported a higher epidemiological stage of CPE than in 
2015, 25 countries described no change and one coun-
try reported, after control of a hospital outbreak [12], an 
improvement of the CPE epidemiological situation [8] 
(Figure 1). Compared with 2015, four additional coun-
tries reported regional or inter-regional spread in 2018, 
thus increasing the number of countries with regional 
or inter-regional spread to 16. The same four countries 
as in 2015 (Greece, Italy, Malta and Turkey) reported an 
endemic situation in 2018 (Figures 1 and 2).
National surveillance and notification of 
cases
In July 2018, 27 countries had a dedicated national sur-
veillance system for CRE and three countries reported 
that they were developing such a system (Table 1). 
Twenty-four countries had national recommendations 
or obligations for notification of CRE cases to health 
authorities (Table 1). Notification to health authorities 
was mandatory for all detected CRE cases (i.e. CRE 
infections and colonisations) in 18 countries. Reporting 
was mandatory for all laboratories in 13 countries. In 
Greece, Italy and Ireland, notification was mandatory 
for invasive infections only, and mandatory notification 
in Belgium was enacted only in outbreak situations. 
Figure 2
Epidemiological situation of carbapenemase-producing Enterobacteriaceae, assessment by national experts in European 
countries, July 2018 (n = 37)
Epidemiological stages
Sporadic occurence (Stage 1)
Single hospital outbreak (Stage 2a)
Sporadic hospital outbreaks (Stage 2b)
Regional spread (Stage 3)
Inter-regional spread (Stage 4)
Endemic situation (Stage 5)
Countries not participating
Luxembourg
Malta
Administrative boundaries: 
© EuroGeographics, ©UN-FAO 
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Table 1
National capacity for surveillance and containment of carbapenem-resistant and carbapenemase-producing 
Enterobacteriaceae, European countries, July 2018 (n = 37)
Country National reference or expert laboratory
National 
surveillance 
system for CRE
National recommendation or 
obligation for notification for 
CRE
National plan for 
containment of CPE
National recommendation or 
guideline on infection control 
measures for CPE
Albania Y N N N N
Austria Y Ya Nb N N
Belgium Y Ya Yc Y Y
Bosnia and Herzegovinad N N Ye N U
Bulgaria Y IP (2018)f IP (2018) IP (2018) IP (2018)
Croatia Y Yg Ye,h Y Y
Cyprus Y Yg N N Y
Czech Republic Y Yg Ye,h Y Y
Denmark Y Ya IP (2018)i Y IP (2018)
Estonia N IP (2020) IP (2020)j N N
Finland Yk Yg Ye,h Y Y
France Y Ya Ye Y Y
Germany Y Ya Ye, h N Y
Greece Yk Yg Yh, l Y Y
Hungary Y Ya Ye IP (2019) Y
Iceland Y Yg Ye, h Y Y
Ireland Y Ya Ym Y Y
Italy Yk Ya Yl Y Y
Kosovon IP Ya IP IP IP
Latvia Y Yg Ye N N
Lithuania Y Yg Ye,h N N
Luxembourg Yk Ya IP (2019) U Y
Malta Yk Ya Ye IP (2018)o Y
Montenegro N N Ye, h N N
The Netherlands Y Ya Y N Y
North Macedonia Yk Yg IP (2019) IP (2019) IP (2019)
Norway Y Yg Ye,h IP (2018/2019) Y
Poland Y Ya Ye,h Y Y
Portugal Y Yg Ye,h Y Y
Romania Yk IP (2019)p Yq IP (2019) Y
Serbia Y N N N N
Slovakia Y Yg Ye,h U Y
Slovenia Yk N N N Y
Spain Y Ya Ye,h Y Y
Sweden Y Yg Ye,h Y Y
Turkey Y N N N IP
UK
England Y Ya Ya Y Y
Northern Ireland Y Ya N N Y
Scotland Y N N Y Y
Wales Y Yg Yg Y Y
CRE: carbapenem-resistant Enterobacteriaceae; CPE: carbapenemase-producing Enterobacteriaceae; IP: in preparation (if a date of planned implementation was provided by 
the country, the year is shown in brackets); N: not in place; U: unknown (i.e. information not available to the respondent); UK: United Kingdom; Y: in place.
a Voluntary participation.
b In Austria, it is recommended for laboratories to report all suspected CPE isolates to the national reference laboratory.
c In Belgium, reporting is mandatory for outbreak situations only.
d The results for reported Bosnia and Herzegovina only apply to Republika Srpska.
e Mandatory notification for all detected cases.
f Bulgaria has a national surveillance system for antimicrobial resistance including CPE, but is planning to implement a dedicated system for CRE.
g Mandatory participation.
h Mandatory notification for all laboratories.
i In Denmark, CPE have been made reportable from 5 September 2018 onwards.
j In Estonia, reporting of resistant microorganisms related to hospital-acquired infections is obligatory and implementation of specific recommendations for CRE is planned.
k A national expert laboratory fulfils a similar role as a national reference laboratory.
l Mandatory notification for specific infections only.
m In Ireland, notification of invasive CPE isolates has been mandatory since 2013, with a national enhanced surveillance system for all new CPE isolates in place since 2016. 
Addition of mandatory notification to health authorities of all new CPE isolates is planned.
n This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the International Court of Justice 
Opinion on the Kosovo declaration of independence.
o For Malta, the national containment plan had been completed at the time of publication.
p Romania currently reports carbapenem-resistant isolates to the European Antimicrobial Resistance Surveillance Network (EARS-Net), but is planning for a dedicated 
national surveillance system for CRE.
q In Romania, reporting of CPE is mandatory when found in hospitals.
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Table 2
Laboratory capacity for genotypic detection and characterisation of carbapenem-resistant Enterobacteriaceae at national 
reference and expert laboratories, European countries, July 2018 (n = 37)
Country Genotypic characterisation at national reference or expert laboratory
Laboratory methods for genetic characterisation used at national 
reference laboratory or expert laboratory
PCR Real-time PCR Single-gene sequencing WGS
Albania N NL NL NL NL
Austria Y Y N N N
Belgium Y Y N Y Y
Bosnia and 
Herzegovinaa NL NL NL NL NL
Bulgaria Y Y Y Y N
Croatia Y Y Y Y N
Cyprus Y N Y N N
Czech Republic Y Y Y Y Y
Denmark Y N N N Y
Estonia NL NL NL NL NL
Finland Y N Y N Y
France Y Y N Y Y
Germany Y Y N Y Y
Greece Y Y N Y N
Hungary Y Y N Y Y
Iceland Y N Y N N
Ireland Y N Y N Y
Italy Y Y N Y Y
Kosovob NL NL NL NL NL
Latvia Y N Y N N
Lithuania Y Y N N N
Luxembourg Y N Y N Y
Malta Y N Y N N
Montenegro NL NL NL NL NL
The Netherlands Y Y N N Y
North Macedonia Y Y Y N N
Norway Y N Y N Y
Poland Y Y N Y Y
Portugal Y Y Y Y Y
Romania Y Y N Y N
Serbia Y Y N N N
Slovakia Y Y N N N
Slovenia Y N Y Y Nc
Spain Y Y Y Y Y
Sweden Y N N N Y
Turkey Y Y N N N
United Kingdom Y Y Y N N
Y: used; N: not used; NL: no national reference or expert laboratory; WGS: whole genome sequencing.
a The results for reported Bosnia and Herzegovina only apply to Republika Srpska.
b This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the 
International Court of Justice Opinion on the Kosovo declaration of independence.
c WGS has become available in Slovenia at the time of publication.
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National capacity for infection control 
measures for carbapenemase-producing 
Enterobacteriaceae and national plan for 
containment
Twenty-four countries reported to have issued national 
recommendations or guidelines for infection control 
measures for patients with confirmed CPE and five 
countries reported preparing these recommendations 
(Table 1). In 2015, 23 countries had reported having 
infection control recommendations for CPE in place [8]. 
In 2018, a national plan for containment of CPE was 
available in 14 countries and was under preparation 
in another seven countries (Table 1). In 2015, only 10 
countries had reported having a national containment 
plan for CPE [8].
National laboratory capacity
Thirty-three countries reported having a NRL or an 
equivalent expert laboratory for CRE and one country 
was preparing for implementing a NRL at the time of 
the assessment (Table 1). Thirty-two of these NRLs or 
equivalent laboratories had the capacity to perform 
genotypic identification or characterisation of CPE 
(Table 2). PCR and real-time PCR were the most fre-
quently used molecular methods (n = 21 and n = 16, 
respectively) (Table 2).
Sixteen NRLs or equivalent laboratories reported 
performing genotypic characterisation of carbap-
enem resistance mechanisms with whole genome 
sequencing (WGS) and 14 reported using single-gene 
sequencing, either in addition to WGS (n = 9) or as 
the only sequencing method (n = 5). All laboratories 
performing genotypic characterisation could iden-
tify bla VIM, bla KPC, bla NDM and bla OXA-48 like, i.e. the most 
common carbapenemase genes [13]. Twenty-six labora-
tories reported testing for additional carbapenemase 
genes such as bla  IMP, bla  GES, bla  FRI, bla  IMI and bla  SME
on a regular basis or when rare carbapenemases were 
suspected. Nine countries reported having national 
guidelines for clinical laboratories on molecular detec-
tion and/or characterisation of carbapenem resistance 
determinants in Enterobacteriaceae; however, further 
information on the implemented methods in individual 
clinical laboratories within countries was not collected 
within this survey.
Discussion
The results of this joint assessment by national experts 
of the epidemiological situation in 37 European coun-
tries indicates that CPE in healthcare systems in Europe 
disseminated further between 2015 and 2018. In 2018, 
20 of 37 countries reported inter-institutional spread 
of CPE within the country (epidemiological stages 3–5) 
and 11 countries reported a worsened epidemiologi-
cal situation compared with 2015 [8]. While this trend 
may in some countries be partially be explained by 
increased awareness and ascertainment capability 
through improved surveillance and diagnostic capacity, 
the latter was already largely in place in the majority of 
EU/EEA countries in 2015 at the end of the EuSCAPE 
project [14], as confirmed by the EULabCap 2016 sur-
vey [15]. However, it cannot be excluded that there is 
still underdetection of CPE in some countries depend-
ing on the frequency of microbiological sampling and 
of screening for CPE. Therefore, the direct comparison 
between countries with different levels of healthcare 
infrastructure and resources should be made with cau-
tion. In addition, the 2010 survey is only of limited use 
as a baseline as this survey was initiated very early in 
the upsurge of CPE and only minimal information was 
available in many countries at this time.
Advanced technical capacity for laboratory detection, 
molecular investigation and surveillance of CRE/CPE 
was widely available in the participating countries in 
2018, especially in countries in the EU and EEA. The 
use of WGS for national surveillance and investiga-
tion of CRE/CPE has rapidly increased in EU/EEA coun-
tries since 2013 [16]. This was confirmed in our survey, 
with 16 EU/EEA countries reporting that they used this 
method for molecular investigation of CRE/CPE in 2018. 
Nevertheless, there are areas for improvement regard-
ing prevention and control policies as more than half 
of the surveyed countries lacked national plans for 
containment of CPE and about a third did not have 
a recommendation or guideline on infection control 
measures for CPE. With many occurrences of cross-bor-
der transfer of CPE reported globally and within Europe 
[17-19], the success of CPE control activities depends 
on all countries having strong surveillance and control 
measures in place.
These results do not provide information on the fac-
tors driving the apparent increasing dissemination of 
CPE in Europe, which would require further investiga-
tions. In this context, a structured survey of CCRE iso-
lates is planned within EURGen-Net and approximately 
300 European hospitals will collect CCRE isolates with 
related epidemiological information in 2019 [20]. The 
isolates will be analysed by WGS to determine the 
presence and distribution of high-risk CCRE clones, 
epidemic clades and successful plasmids carrying car-
bapenemase genes in European hospitals and their 
potential cross-border spread [20]. A more in-depth 
understanding of the molecular epidemiology and 
transmission routes of CPE/CRE in Europe can inform 
risk assessment and allow better targeting of preven-
tion and control efforts.
Conclusion
The presented results show that the ongoing dissemi-
nation of CPE is further expanding across healthcare 
systems in Europe. This trend highlights the need for 
enhanced containment efforts within countries as well 
as concerted action at a European level.
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